|
|
|
Medicines/Products by Categories
|
|
|
|
|
|
|
In today’s world of rapid change, future shock is no longer shocking. To those who do not plan for future, future may come too soon. But to those with careful preparation and accurate anticipation, to those with vision, future is where we are going to prosper. Towards which desirable end, we endeavour today.
With promising molecules in our manufacturing pipeline, we are going to meet our future with great preparation and nonchalance.
For details visit our group company’s website Indswift Labs Limited.
To develop various types of NDDS for selected therapeutic segments. 12 new drug / combination being developed under NDDS to be introduced first time in India.
Contract research
Contract manufacturing
|
|
Joint ventures in marketing finished dosage forms in India, SAARC and South East Asian countries.
- Dedicated to be an integrated healthcare company:
- Chain of Multi -specialty hospitals
- Pharmacy chain
- Chain of diagnostic laboratories
CHRONICLE
2007-2008
Company has achieved the 35th rank among top 300 pharma industries in 2007-08
Company has got international approvals viz. MHRA(UK),TGA(Australia),WHO(Geneva) and other such regularly bodies.
We achieved MoH(UAE),TFDA(Tanzania),NDA(Uganda) and DACA(Ethiopia).
The company's new division Diagnozis dealing in medical equipments and devices was launched in December 2007.
Animal Health Care is another division launched by our company which is absolutely new concept with outsourced marketing.
Ethical marketing Division of the company introduced products during the year viz. Cirrholiv useful in curing Hepatities and other liver disorders.
In Generics,company merged as the 2nd rank Pharma Generic Company
New brands in Generic are Amyclox,Swimox,Oxo,Swiflox and Cafzone achieving the sales growth over 25 crore.
Company's manufacturing unit at Parwanoo has also been upgraded as per WHO standards.
Company's Global Business unit (GBU) at Derabassi has got MHRA & TGA approval.
Manufacturing unit at Baddi(H.P.) received WHO GMP certification for tablet/SVP/Liquid manufacturing.
2006-2007
Company has entered in an advanced stage of Launching its products in the International Markets.
The Company's 100% Export Oriented Global Business Unit,(GBU) is complaint to the GMP specifications of MHRA(UK),TGA(Australia) and other regulatory bodies.
Company also launched its product in Kenya and Senegal.
The Company has filled more than 100 dossiers for registration in about 20 countries around the world stretching from South America to Philippines.
The third new division is Agile which has been launched in joint venture with a Dubai based Pharma company focusing on Pain Management & Anti-infectives.
The Company introduced various new product ranges in the domestic markets through its 12 marketing divisions,a total of 40 offices in India,3000 stockists & superstockists across the country with an enhanced field force of 1400 marketing professionals endeavoring hard in broaden therapeutic segments of Cardiology,Diabetology,Neurology and Oncology.
Company has been ranked 41st among top 50 leading pharmaceutical giants.
Company R&D with available scientific pool of 100 scientists working on different projects on dossiers,DMFS in CTD formats,stability data profile,conceptualization of new molecules,planning for bioequivalence and clinicals.
More than 5% of total revenues have been planned to spend on the company's R&D .
Company's another feather in its cap is its new manufacturing facility for soft gelatin encapsulation with an annual capacity of 35 Crore Soft gelatin Capsules, which will be put into operation during current financial year.
2004-2005
Launched combination of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia.
Ind Swift Group achieved a turnover of 480 crores.
2004
Launched Mukur Division with focus on ophthalmology, neuropsychiatry and ENT.
Another division launched by the name Resurgence catering to the Anesthesiology and Oncology segments.
Ind-Swift group achieved a turnover of INR 375 Crores.
Launched Nitazoxanide, an antidiarrhoeal drug, first time in India after successful clinical trials.
Got DGQA registration
Opened first overseas office in New Jersey, USA
2003
Ind-Swift group achieved a turnover of INR 300 Crores
Launched another division by the name Ind-Swift Biosciences.
Ind-Swift enters into formulations export to 6 countries.
Filed Patent in US for Clarithromycin
2002
Bagged ISO 9001-2000 Certification.
Attained leading position in the world in the products like Clarithromycin granules
Exports to almost 40 countries in the world and set up eleven representative offices worldwide.
2001
Launch of Institution/Hospital Division.
2nd Company to launch Pioglitazone and Candesartan in India
2000
Launched Super Specialty Division (SSD) focusing on Cardiology and Diabetology segments.
1997
A 30 crore multipurpose plant commissioned with five independent blocks erected as per cGMP and US FDA standards, designed by Quara, Switzerland.
Another Marketing Division launched with the name Ind-Swift Health Care.
1996
Ind-Swift floated Ind-Swift Laboratories Limited in 1995 to initiate a backward integration into the manufacturing of APIs and advanced intermediates.
1994
Ind-Swift went public with issues oversubscribed 52 times
1991
Set up a manufacturing facility for injectables and eye/ear drops.
1986
Birth of Ind-Swift limited.
Introduced for the first time in India sustained release tablet of Isoxsuprine HCL
1983
Year of Foundation
|
|
|
|